Compare F5 Inc (FFIV) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F5 Inc vs Sanofi SA — how do they compare? F5 Inc trades at $415.62 (market cap $23.44B), while Sanofi SA trades at $43.6 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 4.4× F5 Inc's market cap, and Sanofi SA pays a 5.55% dividend while F5 Inc pays none. Which is the better fit depends on your goals.
| FFIV | SNY | |
|---|---|---|
Market Cap | $23.44B | $104.30B |
Sector | Technology | Health |
52-Week High | $431.26 | $52.34 |
52-Week Low | $223.99 | $41.33 |
Enterprise Value | $22.08B | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
F5 (FFIV) stock trades at $422.95, up 3.16% on the day, near its 52-week high. The company reported strong Q3 2026 earnings, beating estimates with EPS of $4.73 versus $4.00 expected, driven by 19% product revenue growth. Technical indicators show a bullish trend with support at $411 and resistance at $425. Fundamentals remain solid with revenue growth to $3.09B in 2025 and net income margin of 21.95%.
Outlook is positive given raised revenue guidance and robust cybersecurity demand, but valuation multiples like P/E of 32.98 suggest premium pricing. Risks include competitive pressures and execution challenges in sustaining high growth. Analyst consensus is Moderate Buy with a $430.43 price target, indicating modest upside potential from current levels.
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
